Novel Peptide-Drug Conjugates with Dual Anticancer Activity

Area of Science:

• Medicinal Chemistry
• Biotechnology
• Oncology

Background:

• Cationic antimicrobial peptides (AMPs) possess known antimicrobial and anticancer properties.
• Conjugating AMPs with other bioactive molecules can improve their clinical utility, an approach less explored for anticancer applications.
• Usnic acid derivatives and AMPs individually show selective anticancer activity.

Purpose of the Study:

• To synthesize and evaluate anticancer conjugates by linking usnic acid derivatives to an AMP (L-K6).
• To investigate the effects of these conjugates on cancer cells, specifically targeting tyrosyl-DNA phosphodiesterase 1 (TDP1) and inducing DNA damage.

Main Methods:

• Synthesis of two usnic acid derivatives conjugated to the AMP L-K6 via a pyrazole ligation.
• Evaluation of the conjugates' activity against cancer cells, including their effect on TDP1 and DNA damage.
• Assessment of cytotoxicity against glioblastoma cells.

Main Results:

• The synthesized conjugates, linked by a hydrazone, displayed varied effects on parent drug activity, from reduction to enhancement.
• Conjugates maintained anti-TDP1 activity.
• Cytotoxicity against glioblastoma cells was intermediate or higher compared to individual components.

Conclusions:

• Conjugation of usnic acid derivatives to AMPs is a viable strategy for developing novel anticancer agents.
• The resulting conjugates show promise for glioblastoma treatment due to retained anti-TDP1 activity and enhanced cytotoxicity.
• This approach offers a new avenue for exploring AMPs in cancer therapy.